Selected-GenAtlas references	SOURCE	GeneCards	NCBI Gene	Swiss-Prot	Ensembl
	HGNC	UniGene	Nucleotide	OMIM	UCSC

Home Page

FLASH GENE

Symbol

FLT1

contributors: mct - updated : 21-09-2016

HGNC name	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
HGNC id	3763

FLASH GENE DNA RNA EXPRESSION PROTEIN DISORDER ANIMAL & CELL MODELS

ASSOCIATED DISORDERS

corresponding disease(s)

Other morbid association(s)

Type Gene Modification Chromosome rearrangement Protein expression Protein Function constitutional     --low   in hemangioma endothelial cells, resulting in VEGF-dependent activation of KDR and downstream signaling pathways constitutional     --over   in placentas of preeclampsia and HELLP syndrome constitutional     --over   higher expression in severe preeclampsia or eclampsia than in normal pregnancy constitutional     --over   in coronary artery disease where cardiac tissue has been subjected to prolonged or chronic hypoxia, increased VEGFR1, thus selecting for non-ischemic in endothelial cells in promoting pro-angiogenic responses including nitric oxide production constitutional     --low   loss of expression of FLT1, moderate expression of KDR and high concentration of nitrate associated with aneurysm formation constitutional     --over   concentration of FLT1 in severe preeclampsia is higher compared with normal pregnancy constitutional     --over   contributes to endothelial injury in in IgA nephropathy (IgAN) constitutional     --low   decreased expression of FLT1 in decidua and weaker VEGFA and KDR expression in placental villi and decidua may be associated with early pregnancy loss constitutional     --low   decreased significantly in serum of patients with ALS

Susceptibility

Variant & Polymorphism

Candidate gene
Marker	with PLGF, is an effective biomarker in predicting PE (preeclampsia) during the second trimester, before the clinical onset of PE
	sFLT1 levels may be an effective biomarker to predict the progression of heart failure in patients with coronary artery disease (CAD)
	elevated levels of FLT1 are associated with adverse outcomes in stable patients with heart failure
	FLT1 mRNA expression in maternal blood can be used as a marker to predict the development of fetal growth restriction (FGR), long before a clinical diagnosis is made
	molecular detection of MAML2 rearrangement combined with FLT1 may be of important clinical value for Primary pulmonary mucoepidermoid carcinoma (PMEC)
Therapy target	in treating neovascular diseases
	System Type Disorder Pubmed cardiovascular aquired   potential therapy target in conditions where inducing angiogenesis might be benficial (preeclampsia, wound healing, strocke and heart disease) cancer     therapeutic potential for FLT1-modifying drugs in cancer pain cancer angiogenesis   disrupting PGF/FLT1 pathway could modulate endothelial-colony-forming cells (ECFCs)-induced tubulogenesis, the cell type responsible for newly formed vessels

ANIMAL & CELL MODELS

	Flk1 disrupted transgenic mice
	mdx:Flt-1(+/-) adult mice display a developmentally increased vascular density in skeletal muscle compared with the wild-type and mdx mice (mdx:utrophin(-/-):Flt-1(+/-) mice display improved muscle histology and significantly higher survival rates compared with the mdx:utrophin(-/-) mice, which show more severe muscle phenotypes than the mdx mice)
	loss of normal foot process structure in mice lacking Flt1 results in massive protein leakage into the urine due to disruption of the glomerular permeability barrier, resulting eventually in kidney failure